Trial · NCT00042991
Participant flow35
How many started, completed or left each group, period by period.
1 to 20 of 35
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Stratum 1A-100 mg/m^2 of Gefitinib + Radiation | 6 | |
| Overall Study | STARTED | Stratum 1A-250 mg/m^2 of Gefitinib + Radiation | 43 | |
| Overall Study | STARTED | Stratum 1A-375 mg/m^2 of Gefitinib + Radiation | 7 | |
| Overall Study | STARTED | Stratum-1B: 100 mg/m^2 of Gefitinib + Radiation | 2 | |
| Overall Study | STARTED | Stratum-1B: 250 mg/m^2 of Gefitinib + Radiation | 3 | |
| Overall Study | STARTED | Stratum-1B: 375 mg/m^2 of Gefitinib + Radiation | 5 | |
| Overall Study | STARTED | Stratum-2: 100 mg/m^2 of Gefitinib + Radiation + EIACD | 3 | |
| Overall Study | Phase-I Trial | Stratum 1A-100 mg/m^2 of Gefitinib + Radiation | 6 | |
| Overall Study | Phase-I Trial | Stratum 1A-250 mg/m^2 of Gefitinib + Radiation | 7 | |
| Overall Study | Phase-I Trial | Stratum 1A-375 mg/m^2 of Gefitinib + Radiation | 7 | |
| Overall Study | Phase-I Trial | Stratum-1B: 100 mg/m^2 of Gefitinib + Radiation | 2 | |
| Overall Study | Phase-I Trial | Stratum-1B: 250 mg/m^2 of Gefitinib + Radiation | 3 | |
| Overall Study | Phase-I Trial | Stratum-1B: 375 mg/m^2 of Gefitinib + Radiation | 5 | |
| Overall Study | Phase-I Trial | Stratum-2: 100 mg/m^2 of Gefitinib + Radiation + EIACD | 3 | |
| Overall Study | Phase-II Trial | Stratum 1A-100 mg/m^2 of Gefitinib + Radiation | 0 | |
| Overall Study | Phase-II Trial | Stratum 1A-250 mg/m^2 of Gefitinib + Radiation | 36 | |
| Overall Study | Phase-II Trial | Stratum 1A-375 mg/m^2 of Gefitinib + Radiation | 0 | |
| Overall Study | Phase-II Trial | Stratum-1B: 100 mg/m^2 of Gefitinib + Radiation | 0 | |
| Overall Study | Phase-II Trial | Stratum-1B: 250 mg/m^2 of Gefitinib + Radiation | 0 | |
| Overall Study | Phase-II Trial | Stratum-1B: 375 mg/m^2 of Gefitinib + Radiation | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00042991/flow